It’s actually more than that. In the past decade or so, whenever I’ve heard the CEO of a small biotech company proclaim that the company is “in active discussions with the FDA,” it always turned out to be a harbinger of bad news. The reason is obvious when you think about it: if discussions with the FDA were genuinely progressing in a meaningful way, it would be possible to give specifics on the timing of meetings, submissions, approved protocols, or other concrete milestones.
I’ll make a gentlemen’s bet with you (or anyone else on this board) that a phase-3 Laviv trial for acne scars will not start during the next year and will not finish during the next three years.
Giving discounts to people working in a doctor's office is a no brainer in terms of marketing. There is no better way to advertise a product like laViv than having the people working in a doctor's office actually use it and talk about their experience with patients who come in.
News 
Market Data 
Discover 
AI
